Teva Pharmaceutical Investments Singapore, or TPIS, a subsidiary of Teva, and Jiangsu Nhwa Pharmaceutical announced it formed a partnership for the marketing and distribution of Teva’s Austedo for the treatment of neurodegenerative and movement disorders – chorea associated with Huntington’s disease, or HD, and tardive dyskinesia, or TD, in adults. The partnership intends to increase patients’ access to Teva’s Austedo, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TEVA:
- Alvotech, Teva announce U.S. approval of SIMLANDI injection
- Teva put volume heavy and directionally bearish
- Teva presents data confirming target engagement o TEV-‘574 at ECCO meeting
- Notable open interest changes for February 13th
- Teva Pharmaceutical Industries Limited Is Worried About This – Should You Be Worried Too?